Last reviewed · How we verify
CANNABIGEROL
At a glance
| Generic name | CANNABIGEROL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) (PHASE1)
- CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy (PHASE1)
- The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder (PHASE2)
- Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults (NA)
- Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - (PHASE2,PHASE3)
- Acute Psychological and Physiological Effects of Cannabigerol (NA)
- A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis. (NA)
- Acute Effects of Cannabigerol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CANNABIGEROL CI brief — competitive landscape report
- CANNABIGEROL updates RSS · CI watch RSS